Neurotrope Inc (NTRP)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

1185 AVENUE OF THE AMERICAS NEW YORK, NY 10036

Neurotrope Inc serves as a clinical testing stage biopharmaceutical and diagnostics company. The company focuses on developing drug candidates for the treatment of Alzheimer's Disease.

Data as of 2019-12-03 04:09:03 -0500
Market Cap11.861 Million Shares Outstanding13.068 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS-1.414
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low8.4 / 0.63 Next Earnings Date Price to Cash FLow (P/CF) -5.2427
Data provided by IEX Cloud

Are you looking for this stock instead?

View SEC Filings from NTRP instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding NTRP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NTRP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WEINSTEIN ROBERT SEE REMARKS

  • Officer
0 2020-12-01 2

SINGER WILLIAM S.

  • Director
0 2020-12-01 2

SILVERMAN JOSHUA

  • Director
0 2020-12-01 4

ALKON DANIEL L. SEE REMARKS

  • Officer
0 2020-12-01 2

BERNSTEIN BRUCE

  • Director
0 2020-12-01 2

PERRY GEORGE

  • Director
0 2020-12-01 2

RYAN CHARLES S.

  • Director
  • 10% Owner
0 2020-12-01 2

GERGEL IVAN P.

  • Director
0 2020-12-01 2

SCHECHTER JONATHAN

  • Director
0 2020-12-01 5

CIRAOLO MICHAEL COO AND GENERAL COUNSEL

  • Officer
0 2019-04-15 0

GOTTLIEB JAMES

  • Director
0 2019-03-15 0

PHARES SHANA

  • Director
0 2019-03-15 0

PERLMAN ANDREW D

  • Director
0 2018-03-13 0

WILKE SUSANNE

  • FORMER CHIEF EXECUTIVE OFFICER
No longer subject to file 2017-12-14 0

GORELICK KENNETH J

  • Director
0 2017-03-17 0

TRZEPACZ PAULA T SEE REMARKS

  • Officer
0 2016-06-15 0

RAMAT CHARLES S PRESIDENT AND CEO

  • Officer
  • Director
2,192,605 2015-11-30 0

HAFT JAY M

  • Director
88,252 2015-11-30 0

FREIMAN PAUL E. SEE REMARKS

  • Officer
  • Director
0 2015-11-19 0

ALTSTIEL LARRY DOUGLAS

  • Director
0 2015-11-19 0

CROCKFORD DAVID

  • SEE REMARKS
0 2015-11-18 0

ABELES JOHN H

  • 10% Owner
0 2015-11-13 0

WASIEWSKI WARREN W

  • SEE REMARKS
0 2014-11-01 0

WEISBERG IRA

  • SEE REMARKS
0 2014-08-29 0

NEUROSCIENCES RESEARCH VENTURES, INC.

BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE

  • Director
  • 10% Owner
9,025,000 2014-08-29 0

SCHEYER RICHARD

  • SEE REMARKS
0 2014-08-29 0

NORTHLEA PARTNERS LTD

  • 10% Owner
5,187,000 2014-08-29 0

NEW JAMES

  • 10% Owner
3,646,100 2014-08-29 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments